Therapeutic Treatment of Inhalation Anthrax
5
Pipeline Programs
5
Companies
1
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
4
0
1
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
5100%
On Market (1)
Approved therapies currently available
RAXIBACUMABApproved
raxibacumab
GSKAnthrax Protective Antigen-directed Antibody [EPC]iv (infusion)2012
Competitive Landscape
5 companies ranked by most advanced pipeline stage
Human BioSciencesWV - Martinsburg
1 program1
RaxibacumabPhase 2/3Monoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Human BioSciencesRaxibacumab
Clinical Trials (1)
Total enrollment: 20 patients across 1 trials
An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection
Start: Jan 2008Est. completion: May 200820 patients
Phase 2/3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
5 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.